Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-06-26 Report Publication Anno…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia presents full-year report and status in the Board's review through audiocast on June 28
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) inviting investors to an audiocast and conference call to discuss the company's full-year report. It does not contain the report itself, but rather serves as a notification of the upcoming presentation and provides access links. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2019-06-26 English
Oasmia presents full-year report and status in the Board's review through audiocast on June 28
Report Publication Announcement Classification · 99% confidence The document explicitly states that Oasmia "will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019...". It provides details for the audiocast and conference call, and includes an attachment titled "PM inbjudan audiocast Q4 ENG" (PM invitation audiocast Q4 ENG). This structure—announcing a future event to present a report (the full-year report) along with access details—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself (10-K) but the announcement of the presentation of that report.
2019-06-26 English
Two studies finalized in Oasmia Pharmaceutical’s Docecal programme
Regulatory Filings Classification · 95% confidence The document is a press release from Oasmia Pharmaceutical AB announcing clinical trial results for their drug 'Docecal'. It provides a summary of the study findings (safety and efficacy) and includes contact information. While it contains an attachment link at the bottom, the text itself is a substantive announcement of clinical results rather than just a notification of a report's publication. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a general regulatory announcement regarding company developments, it is classified as a Regulatory Filing (RNS).
2019-06-25 English
Two studies finalized in Oasmia Pharmaceutical’s Docecal programme
Regulatory Filings Classification · 95% confidence The document is a press release from Oasmia Pharmaceutical AB announcing clinical trial results for their drug 'Docecal'. It provides a summary of the study findings (safety and efficacy) and includes contact information. While it contains an attachment link at the bottom, the text itself is a substantive announcement of clinical results rather than just a notification of a report's publication. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a general regulatory announcement regarding company developments, it is classified as a Regulatory Filing (RNS).
2019-06-25 English
Two studies finalized in Oasmia Pharmaceutical’s Docecal programme
Regulatory Filings Classification · 99% confidence The document text is a press release announcing the results from two clinical studies (Phase I and Phase II/safety) comparing a new formulation (Docecal) against an existing drug (Taxotere) for metastatic breast cancer. It details safety and efficacy findings and concludes with a summary of the results. The final section includes a statement that the information is 'inside information' that the company is obliged to make public pursuant to the EU Market Abuse Regulation, and it is dated June 25, 2019. This structure—a formal announcement of material, non-public information regarding clinical trial outcomes—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses purely on the results announcement rather than a full quarterly financial report (IR) or a management discussion (MDA), and it is a direct release of material news, 'Earnings Release' (ER) is the most appropriate fit for announcing key performance/trial results, even if it's not strictly quarterly earnings. It is not a Call Transcript (CT) or a full Annual Report (10-K). Given the nature of reporting clinical trial outcomes which often accompany or precede financial reporting periods, ER is selected over the generic RNS.
2019-06-25 English
Två studier genomförda i Oasmia Pharmaceuticals Docecal-program
Earnings Release Classification · 99% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated June 25, 2019, announcing the results from two clinical studies (Phase I and Phase II) of the drug candidate Docecal for metastatic breast cancer. It details safety and efficacy data compared to Taxotere®. The text concludes with a statement that the information is subject to disclosure under EU market abuse regulation and provides contact information. This format—a formal announcement of significant operational/clinical results—most closely aligns with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of clinical trial results rather than a comprehensive quarterly financial report (IR) or a general regulatory filing, and it is not a transcript (CT) or an investor presentation (IP), it functions as an immediate release of material information. Given the options, 'ER' (Earnings Release) is often used broadly for material operational updates that impact valuation, but 'RNS' (Regulatory Filings) is the most appropriate fallback for specific, non-financial regulatory announcements like clinical trial updates, especially when the document structure is a short press release announcing findings rather than the full financial results themselves. However, since the content is purely scientific/clinical results, and not explicitly financial earnings, RNS is the best fit as a specific announcement that doesn't fit other categories like ER (which usually focuses on revenue/profit). Given the context of immediate disclosure of material information, RNS is the most accurate general regulatory category for this type of announcement. FY 2019
2019-06-25 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.